Month: July 2023

Review of 505(b)(2) Drug Products Approved by USFDA from 2010 to 2020: A Focus on Intellectual Property and Regulatory Considerations

A review article in the Journal of Pharmaceutical Sciences analyzes the trends in drug repurposing through the 505(b)(2) pathway, as […]

Here’s a summary of a new article that used DrugPatentWatch data: NIH Funding for Patents That Contribute to Market Exclusivity

While answering a question for a DrugPatentWatch user, the question arose of technologies the NIH has licensed. It turns out

In a recent article published by IAM Magazine, titled “Why Pharma Companies Should File Patents Later In The R&D Process,”